Puma Biotechnology (PBYI) Accumulated Expenses (2011 - 2026)

Puma Biotechnology's Accumulated Expenses history runs 16 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• Quarterly Accumulated Expenses fell 80.06% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 80.06% YoY) and the FY2025 annual result came in at $50.0 million, up 35.59% from the prior year.
• Accumulated Expenses was $5.4 million for Q1 2026 at Puma Biotechnology, down from $50.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $53.0 million in Q4 2022 and bottomed at $590000.0 in Q3 2025.
• A 5-year average of $23.1 million and a median of $26.9 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 5721.51% — and 2025, when it plunged 98.84%.
• Puma Biotechnology's Accumulated Expenses stood at $53.0 million in 2022, then sank by 88.88% to $5.9 million in 2023, then surged by 525.39% to $36.9 million in 2024, then soared by 35.59% to $50.0 million in 2025, then tumbled by 89.29% to $5.4 million in 2026.
• Business Quant data shows PBYI's Accumulated Expenses at $5.4 million in Q1 2026, $50.0 million in Q4 2025, and $590000.0 in Q3 2025.